Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovinaciclib + AI + Dual HER2 Blockade in HR+/HER2+ Early Breast Cancer
NCT07616427Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ongiciclib in breast cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Total Pathological Complete Response Rate at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
ongiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07616427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616427.